Presentation is loading. Please wait.

Presentation is loading. Please wait.

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Published byClarence Ramsey Modified over 4 years ago

Similar presentations

Presentation on theme: "Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta."— Presentation transcript:

1 Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta blockers (BB), ACE inhibitors (ACEi) or optimal therapy (one or both of ACEi and BB) compared with wha... Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta blockers (BB), ACE inhibitors (ACEi) or optimal therapy (one or both of ACEi and BB) compared with what patients actually received from 2010 to 2013. QALY, quality-adjusted life-year. Simon Walker et al. Open Heart 2017;4:e000726 ©2017 by British Cardiovascular Society

Download ppt "Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta."

Similar presentations

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.
New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.
WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,
Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.
Fig. 2. Evidence-based medication prescriptions

Fig. 2. Evidence-based medication prescriptions
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.
HOMA calculations where glucose is mmol/L and insulin is mU/L

HOMA calculations where glucose is mmol/L and insulin is mU/L
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.

Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.
Comparison of CMR and echocardiography in aortic regurgitation.

Comparison of CMR and echocardiography in aortic regurgitation.
Trends and inequities in beta-blocker prescribing for heart failure

Trends and inequities in beta-blocker prescribing for heart failure
Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.
The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

The proportion of patients confronted with a cardiovascular risk factor (CVRF) they were previously unaware of, referring to the instrument based tests.

Similar presentations

Ads by Google